JP2017516828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516828A5 JP2017516828A5 JP2016571118A JP2016571118A JP2017516828A5 JP 2017516828 A5 JP2017516828 A5 JP 2017516828A5 JP 2016571118 A JP2016571118 A JP 2016571118A JP 2016571118 A JP2016571118 A JP 2016571118A JP 2017516828 A5 JP2017516828 A5 JP 2017516828A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pharmaceutically acceptable
- acceptable salt
- dione
- quinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14170974 | 2014-06-03 | ||
| EP14170974.1 | 2014-06-03 | ||
| PCT/IB2015/054173 WO2015186062A1 (en) | 2014-06-03 | 2015-06-02 | PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516828A JP2017516828A (ja) | 2017-06-22 |
| JP2017516828A5 true JP2017516828A5 (enExample) | 2018-06-28 |
| JP6560257B2 JP6560257B2 (ja) | 2019-08-14 |
Family
ID=50841688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016571118A Expired - Fee Related JP6560257B2 (ja) | 2014-06-03 | 2015-06-02 | ピリミド［４，５−ｂ］キノリン−４，５（３Ｈ，１０Ｈ）−ジオン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9896448B2 (enExample) |
| EP (1) | EP3152208B1 (enExample) |
| JP (1) | JP6560257B2 (enExample) |
| CN (1) | CN106459041B (enExample) |
| ES (1) | ES2743184T3 (enExample) |
| WO (1) | WO2015186062A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3152207B1 (en) | 2014-06-03 | 2019-05-08 | Novartis AG | Pyridopyrimidinedione derivatives as suppressors of non-sens mutations |
| MY178379A (en) | 2014-06-03 | 2020-10-09 | Novartis Ag | Naphthyridinedione derivatives as suppressors of non-sense mutations |
| WO2019225625A1 (ja) * | 2018-05-23 | 2019-11-28 | 京都薬品工業株式会社 | リードスルー誘導剤およびその医薬用途 |
| WO2024194607A1 (en) * | 2023-03-17 | 2024-09-26 | Tay Therapeutics Limited | Pyrimido[4,5-b][1,5]naphthyridine-4,5(3h,10h)-dione derivatives for the treatment of diseases associated with ptc mutations, such as e.g. cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2884170B2 (ja) | 1989-08-24 | 1999-04-19 | 株式会社フジモト・ブラザーズ | ５−デアザフラビン系化合物を有効成分とする制癌剤 |
| JP2989871B2 (ja) | 1989-08-30 | 1999-12-13 | 大日本製薬株式会社 | 三環式化合物 |
| JP2991382B2 (ja) * | 1990-07-18 | 1999-12-20 | 大日本製薬株式会社 | 縮合三環式化合物およびその塩 |
| WO1996028444A1 (en) | 1995-03-15 | 1996-09-19 | Pfizer Inc. | 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS |
| US6037345A (en) * | 1998-01-13 | 2000-03-14 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazolinedione and pyridopyrimidinedione derivatives |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2003249244A1 (en) | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| BR0317183A (pt) * | 2002-12-12 | 2005-11-01 | Pharmacia Corp | Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno |
| HUE031794T2 (en) | 2003-04-11 | 2017-08-28 | Ptc Therapeutics Inc | 1,2,4-oxadiol-benzoic acid compounds and their use for nonsense suppression and disease treatment |
| PL2390255T3 (pl) | 2006-04-03 | 2017-01-31 | Technion Research & Development Foundation Ltd. | Nowe aminoglikozydy i ich zastosowania w leczeniu zaburzeń genetycznych |
| WO2008024433A2 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
| WO2008084236A1 (en) * | 2007-01-11 | 2008-07-17 | Astrazeneca Ab | Chemical compounds 635 : pyridopyrimidinediones as pde4 inhibitors |
| JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| EP2422817A1 (en) | 2010-07-29 | 2012-02-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flavin-nucleic acid ligand conjugates |
| CA2806825C (en) | 2010-08-05 | 2018-08-21 | Institut Pasteur De Lille | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound |
| CA2890692A1 (en) | 2012-12-13 | 2014-06-19 | Novartis Ag | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
| EP3152207B1 (en) * | 2014-06-03 | 2019-05-08 | Novartis AG | Pyridopyrimidinedione derivatives as suppressors of non-sens mutations |
| MY178379A (en) * | 2014-06-03 | 2020-10-09 | Novartis Ag | Naphthyridinedione derivatives as suppressors of non-sense mutations |
-
2015
- 2015-06-02 US US15/315,582 patent/US9896448B2/en active Active
- 2015-06-02 CN CN201580028771.4A patent/CN106459041B/zh not_active Expired - Fee Related
- 2015-06-02 JP JP2016571118A patent/JP6560257B2/ja not_active Expired - Fee Related
- 2015-06-02 EP EP15731120.0A patent/EP3152208B1/en not_active Not-in-force
- 2015-06-02 WO PCT/IB2015/054173 patent/WO2015186062A1/en not_active Ceased
- 2015-06-02 ES ES15731120T patent/ES2743184T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018021046A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| NZ723271A (en) | Fused imidazole derivatives useful as ido inhibitors | |
| EP4420679A3 (en) | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| JP2015537020A5 (enExample) | ||
| JP2019521988A5 (enExample) | ||
| RU2018106453A (ru) | Соединения | |
| JP2014502641A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2017516828A5 (enExample) | ||
| JP2016516773A5 (enExample) | ||
| JP2015512432A5 (enExample) | ||
| JP2015521617A5 (enExample) | ||
| JP2017513809A5 (enExample) | ||
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| JP2016529285A5 (enExample) | ||
| JP2015528501A5 (enExample) | ||
| JP2014515407A5 (enExample) | ||
| JP2017516829A5 (enExample) | ||
| JP2018522927A5 (enExample) | ||
| EA201301266A1 (ru) | Фармацевтическая композиция, содержащая налбуфина гидрохлорид, ее применение для лечения болевого синдрома средней и высокой интенсивности и способ получения фармацевтической композиции | |
| JPWO2022250170A5 (enExample) |